Scientific Online Resource System

Scripta Scientifica Pharmaceutica

Biopharmaceutical and marketing evaluation of diosmin- and hesperidin-containing products on the Bulgarian market

Nadezhda Antonova Ivanova, Yozlem Hyusein, Iliya Zhelev Slavov, Ivo Kumanov

Abstract

Introduction

Diosmin and hesperidin are commonly used flavonoids in the therapy of vascular diseases.

Aim

This study aimed to present an independent evaluation of the market status, quality and biopharmaceutical characteristics of diosmin- and hesperidin-containing oral tablet-products (DHCPs) on the Bulgarian market.

Materials and Methods

Seven products, among which medicines (used as reference) and food supplements, with sustainable or growing market were selected for the survey: Detralex 500 mg, Phlebodia 600 mg, Dioket 600 mg, Novarix 650 mg, Asketon 500 mg, Venocode and Dih max 1000 mg. Sales analysis for 2016, 2017 and 2018 (year-to-date) was done with the kind support of Iqvia TM. All products were subjected to European Pharmacopoeia (EP) tests for tablet quality - disintegration, resistance to crushing, uniformity of mass and uniformity of dosage units. Biopharmaceutical profile regarding tablet drug release and dissolution potency was investigated on EP Apparatus 2 (Paddle method).

Results

Although all products were found to almost fully fulfill the EP criteria, extremely unsatisfying drug release was established in all tested media (pH 1,5, pH 4,5 and pH 7,2), reaching not more than 1.6% of the labeled content after 24 hours for the best performing products – Novarix and Venocode. 

Conclusion

These results were not surprising considering diosmin and hesperidin’s water insolubility and respective low bioavailability. However, it would be reasonable to approach these two bioactive compounds technologically in preformulation stage in order to improve their solubility and therapeutic potency.


Keywords

diosmin; hesperidin; medicines; food supplements; tablets quality; drug release

Full Text


References

Thorne Research, Inc. Monograph. Diosmin. Altern Med Rev. 2004;9(3):308-11.

Bogucka-Kocka A, Woźniak M, Feldo M, Kockic J, Szewczyk K. Diosmin-isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use. Nat Prod Commun. 2013;8(4):545-50.

Szymański M, Młynarek D, Szymański A, Matławska I. Simultaneous Determination of diosmin and hesperidin in pharmaceuticals by RPLC using ionic liquids as mobile phase modifiers. Iran J Pharm Res. 2016;15(1):141-8.

Londoño-Londoño J, Lima VR de, Lara O, Gil A, Pasa TBC, Arango GJ, et al. Clean recovery of antioxidant flavonoids from citrus peel: Optimizing an aqueous ultrasound-assisted extraction method. Food Chem. 2010;119(1):81–7. doi: 10.1016/j.foodchem.2009.05.075.

El-Shafae AM, El-Domiaty MM. Improved LC methods for the determination of diosmin and/or hesperidin in plant extracts and pharmaceutical formulations. J Pharm Biomed Anal. 2001;26(4):539-45.

Bunaciu AA, Udristioiu GE, Ruţă LL, Fleschin S, Aboul-Enein HY. Determination of diosmin in pharmaceutical formulations using Fourier transform infrared spectrophotometry. Saudi Pharm J. 2009;17(4):303-6. doi: 10.1016/j.jsps.2009.10.008.

Russo R, Chandradhara D, De Tommasi N. Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers. Molecules. 2018;23(9). doi: 10.3390/molecules23092174.

Mauludin R, Müller R. Physicochemical properties of hesperidin nanocrystal. J Pharm Pharm Sci. 2013;5(3): 954-60. doi: 10.1016/j.ejps.2008.12.002.

Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction. Phlebolymphology. 2016;23(2):82-91. doi: 10.1053/j.semvascsurg.2015.06.001.

Srilatha D, Nasare M, Nagasandhya B, Prasad V, Diwan P. Development and validation of UV spectrophotometric method for simultaneous estimation of hesperidin and diosmin in the pharmaceutical dosage form. ISRN Spectroscopy.2013;1–4. doi: 10.1155/2013/534830.

Aboul-Enein HY. A spectrophotometric method for diosmin determination. Open Chem Biomed Meth J. 2010;3(1):123–7.

Silvestro L, Tarcomnicu I, Dulea C, Attili NRBN, Ciuca V, Peru D, et al. Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquid-chromatography–mass spectrometry and ion mobility mass spectrometry. Anal Bioanal Chem. 2013;405(25):8295–310. doi: 10.1007/s00216-013-7237-y.

Iordachescu A, Silvestro L, Rizea Savu S, Tarcomnicu I, Moise A. Diosmetin pharmacokinetic following diosmin oral administration in man; A new study on an old product with controversial pharmacokinetic findings in the past. J Bioequiv Availab. 2012;4(3). doi: 10.4172/0975-0851.S1.02

Ai F, Ma Y, Wang J, Li Y. Preparation, physicochemical characterization and in - vitro dissolution studies of diosmin-cyclodextrin inclusion complexes. Iran J Pharm Res. 2014 Fall;13(4):1115-23.

Bano S, Javed K, Ahmad S, Rathish IG, Singh S, Chaitanya M, et al. Synthesis of some novel chalcones, flavanones and flavones and evaluation of their anti-inflammatory activity. Eur J Med Chem. 2013;65:51-9. doi: 10.1016/j.ejmech.2013.04.056.

Lokhande PD, Sakate SS, Taksande KN, Navghare B. Dimethylsulfoxide–iodine catalysed deprotection of 2′-allyloxychalcones: synthesis of flavones. Tetrahedron Lett. 2005;46(9):1573–4. doi: 10.1016/j.tetlet.2004.12.041.

Nawghare BR, Gaikwad SV, Raheem A, Lokhande PD. Iodine catalyzed cascade synthesis of flavone derivatives from 2'-allyloxy-α, β-dibromochalcones. J Chil Chem Soc. 2013;59(1), 2284-6. doi: 10.4067/S0717-97072014000100009.

Matsuura S, Iinuma M, Ishikawa K, Kagei K. Synthetic studies of the flavone derivatives. V. The use of DDQ in the dehydrogenation of flavanones. (I). Chem Pharm Bull. 1978;26(1):305-06. doi: 10.1248/cpb.26.305.

Council of Europe. European Pharmacopoeia 8th ed. Strasbourg: Council of Europe; Diosmin. 2008; 2072-73.

Sher E, Codignola A, Biancardi E, Cova D, Clementi F. Amine uptake inhibition by diosmin and diosmetin in human neuronal and neuroendocrine cell lines. Pharmacol Res. 1992;26(4):395–402.

Beiler JM, Martin GJ. Inhibition of hyaluronidase action by derivatives of hesperidin. J Biol Chem. 1948;174:31-35.

Leopoldini M, Russo N, Toscano M. The molecular basis of working mechanism of natural polyphenolic antioxidants. Food Chem. 2011;125(2):288–306. doi: 10.1016/j.foodchem.2010.08.012.

Guerrero L, Castillo J, Quiñones M, Garcia-Vallvé S, Arola L, Pujadas G, et al. Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. PLoS ONE. 2012;7(11): e49493. doi: 10.1371/journal.pone.0049493.

Park HJ, Kim MJ, Ha E, Chung JH. Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine. 2008;15(1-2):147-51. doi: 10.1016/j.phymed.2007.07.061.

Iranshahi M, Rezaee R, Parhiz H, Roohbakhsh A, Soltani F. Protective effects of flavonoids against microbes and toxins: The cases of hesperidin and hesperetin. Life Sci. 2015;137:125-32. doi: 10.1016/j.lfs.2015.07.014.

Kaur H, Kaur G. A critical appraisal of solubility enhancement techniques of polyphenols. J Pharm. 2014;2014:1–14. doi: 10.1155/2014/180845.




DOI: http://dx.doi.org/10.14748/ssp.v5i2.5589

Refbacks

About The Authors

Nadezhda Antonova Ivanova
Medical University of Varna
Bulgaria

Department of Pharmaceutical Technologies, Faculty of Pharmacy

 

Yozlem Hyusein
Medical University of Varna
Bulgaria

Student, Faculty of Pharmacy

Iliya Zhelev Slavov
Medical University of Varna
Bulgaria

Department of Biology, Faculty of Pharmacy

Ivo Kumanov
Medical University of Varna
Bulgaria

Department of Organization and Economics of Pharmacy, faculty of Pharmacy

Font Size


|